.Net Company Develop Thousand Oaks 
socalTECH
AUGUST 26, 2013
Thousand Oaks-based biotech giant Amgen announced Sunday that it has acquired San Francisco biopharmaceuticals company Onyx Pharmaceuticals , in a deal worth $10.4 Onyx is a developer of biopharmaceuticals used to help patients with cancer. billion net of the estimated cash on hand at Onyx. The deal is worth $9.7
socalTECH
JANUARY 27, 2011
In a sign that Thousand Oaks-based Nexsan might be ramping up its IPO efforts again, after a delay last year, the firm filed an updated S-1 this week. The provider of data storage equipment reported that it had net income of $0.5M in net income of $19.28M in revenues for the three months ended September 30, 2010.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
MAY 23, 2011
Thousand Oaks-based Ceres , the developer of seeds aimed at producing renewable, biomass feedstocks for the biofuels industry, has filed for an IPO. According to a filing this morning by the firm, the company is aiming to raise up to $100M in an IPO on the NASDAQ Global Market as CERE. and Barclays Capital.
socalTECH
JUNE 17, 2010
a developer of high speed, analog semiconductors, has filed for an IPO, saying late Wednesday evening in a filing with the SEC it is looking to raise up to $115M in an IPO on the NYSE. The IPO is being underwritten by Morgan Stanley, Deutsche Bank Securities, Jeffries & Company, Thomas Weisel Partners, and Needham & Company.
Xconomy
AUGUST 26, 2016
The company shares rights to its lead drug enzalutamide (Xtandi) with Astellas Pharma and its second drug, talazoparib, a type of cancer treatment called a PARP inhibitor, awaits crucial Phase 3 data next year. The company gave no reason for the rejection. Whether Medivation will be worth the price remains to be seen. Morgan party.
Expert insights. Personalized for you.
153 
Let's personalize your content